Xiao-Yan Si (Xiaoyan Si, Si Xiaoyan)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 34

Top Venues

Thoracic cancer

Therapeutic advances in medical oncology

American journal of respiratory and critical care medicine

Peking Union Medical College Hospital

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Peking Union Medical College Hospital

China

attending physician :: Respiratory Medicine

Publications

Jing Zhao, Yang Wu, Yuan Yue, Min-Jiang Chen, Yan Xu, Xiangning Liu, Xiaoyan Liu, Xiaoxing Gao, Hanping Wang, Xiao-Yan Si, Wei Zhong, Xiao-Tong Zhang, Li Zhang, Mengzhao Wang
The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer. Thoracic cancer 14 (5) (2023)
Jing Zhao, Yang Wu, Yuan Yue, Min-Jiang Chen, Yan Xu, Xiangning Liu, Xiaoyan Liu, Xiaoxing Gao, Hanping Wang, Xiao-Yan Si, Wei Zhong, Xiao-Tong Zhang, Li Zhang, Mengzhao Wang
The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer. Thoracic cancer 14 (5) (2023)
Kang Miao, Xiao-Tong Zhang, Hanping Wang, Xiao-Yan Si, Li Zhang
Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer. Thoracic cancer (2023)
Jing Zhao, Yang Wu, Yuan Yue, Min-Jiang Chen, Yan Xu, Xiangning Liu, Xiaoyan Liu, Xiaoxing Gao, Hanping Wang, Xiao-Yan Si, Wei Zhong, Xiao-Tong Zhang, Li Zhang, Mengzhao Wang
The development of a tumor-associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor-based treatment in patients with advanced non-small-cell lung cancer. Thoracic cancer (2023)
Xiao-Yan Si, Xueqing Zheng, Xinlun Tian, Hanping Wang, Yan Xu, Jing Zhao, Min-Jiang Chen, Wei Zhong, Mengzhao Wang, Li Zhang, Xiao-Tong Zhang
Analysis of cytokines in bronchoalveolar lavage fluid in patients with checkpoint inhibitor pneumonitis and pulmonary infection: A case-control study. Thoracic cancer (2023)
Xiaoxing Gao, Ruili Pan, Min-Jiang Chen, Jing Zhao, Wei Zhong, Hanping Wang, Xiao-Yan Si, Xiao-Tong Zhang, Li Zhang, Yan Xu, Mengzhao Wang
Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis. Thoracic cancer 13 (7) (2022)
Jun Ni, Xiao-Yan Si, Li Zhang
Non-small-cell lung cancer with ERBB2 mutation in non-tyrosine kinase domain benefits from pyrotinib: A case report. Thoracic cancer 12 (8) (2021)
Jun Ni, Xiao-Tong Zhang, Hanping Wang, Xiao-Yan Si, Yan Xu, Jing Zhao, Min-Jiang Chen, Li Zhang, Mengzhao Wang
Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8-year period. Thoracic cancer 13 (4) (2021)
Peng Song, Dongliang Yang, Hanping Wang, Xiaoxia Cui, Xiao-Yan Si, Xiao-Tong Zhang, Li Zhang
Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients. Thoracic cancer 11 (6) (2020)
Peng Song, Xiaotong Zhang, Dongliang Yang, Hanping Wang, Xiao-Yan Si, Li Zhang
Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer. Thoracic cancer 11 (5) (2020)
Xiao-Yan Si, Ruili Pan, Shaohua Ma, Lin Li, Li Liang, Ping Zhang, Yuping Chu, Hanping Wang, Mengzhao Wang, Xiao-Tong Zhang, Li Zhang
Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer. Thoracic cancer 12 (3) (2020)
Hanping Wang, Jiaxin Zhou, Xiaoxiao Guo, Yue Li, Lian Duan, Xiao-Yan Si, Li Zhang
Use of glucocorticoids in the management of immunotherapy-related adverse effects. Thoracic cancer 11 (10) (2020)
Xiao-Yan Si, Peng Song, Jun Ni, Mingyi Di, Chunxia He, Li Zhang, Xiaowei Liu, Yue Li, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Xu Yang, Mengzhao Wang, Li Zhang
Management of immune checkpoint inhibitor-related adverse events: A review of case reports. Thoracic cancer 11 (3) (2020)
Jun Ni, Wang Hanping, Xiao-Yan Si, Yan Xu, Wang Mengzhao, Xiao-Tong Zhang, Zhang Li
Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study. Thoracic cancer 11 (7) (2020)
Xiao-Yan Si, Juhong Shi
Pulmonary and Skeletal Infection of Mycobacterium kansasii. American journal of respiratory and critical care medicine 202 (8) (2020)
Xiao-Yan Si, Yan You, Xiaotong Zhang, Hanping Wang, Mengzhao Wang, Li Zhang
Histologic transformation of lung cancer during pembrolizumab therapy: A case report. Thoracic cancer 11 (3) (2020)
Peng Song, Dongliang Yang, Hanping Wang, Xiaoxia Cui, Xiao-Yan Si, Xiao-Tong Zhang, Li Zhang
Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients. Thoracic cancer 11 (6) (2020)
Hanping Wang, Ruili Pan, Xiaotong Zhang, Xiao-Yan Si, Mengzhao Wang, Li Zhang
Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib. Thoracic cancer 11 (3) (2020)
Minya Lu, Li Zhang, Yue Li, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Xiao-Yan Si, Yingchun Xu, Li Zhang
Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. Thoracic cancer 11 (3) (2020)
Xiao-Wei Liu, Zheng Wang, Chan Zhao, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Xiao-Yan Si, Li Zhang, Yue Li, Mengzhao Wang, Meifen Zhang, Li Zhang
Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy. Thoracic cancer 11 (3) (2020)
Xiao-Yan Si, Hanping Wang, Xiao-Tong Zhang, Mengzhao Wang, Yan You, Li Zhang
Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum-pemetrexed: The first report of two cases. Thoracic cancer 11 (8) (2020)
Xiao-Yan Si, Jinwan Wang, Ying Cheng, Jianhua Shi, Liying Cui, Helong Zhang, Yunchao Huang, Wei Liu, Lei Chen, Jiang Zhu, Shucai Zhang, Wei Li, Yan Sun, Hanping Wang, Xiaotong Zhang, Mengzhao Wang, Lin Yang, Li Zhang
A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer. Therapeutic advances in medical oncology 12 (2020)
Ke Zheng, Wei Qiu, Hanping Wang, Xiao-Yan Si, Xiaotong Zhang, Li Zhang, Xuemei Li
Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor-induced renal immune-related adverse events. Thoracic cancer 11 (6) (2020)
Yue Li, Xiaohui Kang, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Xiao-Yan Si, Li Zhang, Xiao-Wei Liu, Jiaming Qian, Li Zhang
Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system. Thoracic cancer 11 (4) (2020)
Junling Zhuang, Jianhua Du, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Wei Qiu, Xiao-Yan Si, Li Zhang, Yue Li, Xiaowei Liu, Hanping Wang, Daobin Zhou, Li Zhang
Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events. Thoracic cancer 11 (3) (2020)
Ziwei Liu, Tao Liu, Xiao-Tong Zhang, Xiao-Yan Si, Hanping Wang, Jingjia Zhang, Hui Huang, Xuefeng Sun, Jinglan Wang, Mengzhao Wang, Li Zhang
Opportunistic infections complicating immunotherapy for non-small cell lung cancer. Thoracic cancer 11 (6) (2020)
Lian Duan, Linjie Wang, Hanping Wang, Xiao-Yan Si, Li Zhang, Xiao-Wei Liu, Yue Li, Xiaoxiao Guo, Jiaxin Zhou, Huijuan Zhu, Li Zhang
Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction. Thoracic cancer 11 (4) (2020)
Xiao-Yan Si, Chunxia He, Li Zhang, Xiaowei Liu, Yue Li, Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Lian Duan, Mengzhao Wang, Li Zhang
Management of immune checkpoint inhibitor-related dermatologic adverse events. Thoracic cancer 11 (2) (2019)
Xiaoxiao Guo, Hanping Wang, Jiaxin Zhou, Yue Li, Lian Duan, Xiao-Yan Si, Li Zhang, Ligang Fang, Li Zhang
Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity. Thoracic cancer 11 (2) (2019)
Xiao-Yan Si, Li Zhang, Hanping Wang, Xiaotong Zhang, Mengzhao Wang, Baohui Han, Kai Li, Qiming Wang, Jianhua Shi, Zhehai Wang, Ying Cheng, Yuan-Kai Shi, Weiqiang Chen, Xiuwen Wang, Yi Luo, Kejun Nan, Faguang Jin
Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. Thoracic cancer 10 (3) (2019)
Hanping Wang, Xiaoxiao Guo, Jiaxin Zhou, Yue Li, Lian Duan, Xiao-Yan Si, Li Zhang, Xiaowei Liu, Mengzhao Wang, Juhong Shi, Li Zhang
Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis. Thoracic cancer 11 (1) (2019)
Jiaxin Zhou, Hanping Wang, Xiaoxiao Guo, Qian Wang, Lian Duan, Xiao-Yan Si, Li Zhang, Xiaowei Liu, Yue Li, Wen Zhang, Li Zhang
Management of immune checkpoint inhibitor-related rheumatic adverse events. Thoracic cancer 11 (1) (2019)
Shafei Wu, Xiaohua Shi, Xiao-Yan Si, Yuanyuan Liu, Tao Lu, Li Zhang, Zhiyong Liang, Xuan Zeng
EGFR T790M detection in formalin-fixed paraffin-embedded tissues of patients with lung cancer using RNA-based in situ hybridization: A preliminary feasibility study. Thoracic cancer 10 (10) (2019)
Xiao-Yan Si, Shafei Wu, Hanping Wang, Xiaotong Zhang, Mengzhao Wang, Xuan Zeng, Li Zhang
Nimotuzumab combined with chemotherapy as first-line treatment for advanced lung squamous cell carcinoma. Thoracic cancer 9 (8) (2018)

Xiao-Yan Si.css-eqlu8i{font-size:small;padding-left:4px;} (Xiaoyan Si, Si Xiaoyan)

Publication Activity (10 Years)

Top Topics

Top Venues

Xiao-Yan Si (Xiaoyan Si, Si Xiaoyan)